Method for stromal corneal repair and refractive alteration

Abstract

A method and means of providing stromal repair and improved refractive correction by creating corneal stromal collagen tissue with fibril diameter and spacing that duplicates the optical transmission and diffusion characteristics of natural corneal collagen. The repair method includes implanting the collagen scaffold during laser corneal ablation or other interlamellar surgery to improve visual acuity or to preclude the possibility of ectasia

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This is a DIVISIONAL of application Ser. No. 10 / 414,796 filed on Sep. 28, 2005 [0002] This application claims patent priority of provisional Patent Application Ser. No. 60 / 373,725, filed Apr. 16th, 2002. [0003] In addition, Disclosure Documents Nos. 502428 and 503243 filed Dec. 7th, 2001 and Dec. 29th, 2001 respectively.FEDERALLY SPONSORED RESEARCH [0004] Not applicable SEQUENCE LISTING OR PROGRAM [0005] Not Applicable BACKGROUND OF THE INVENTION [0006] 1. Field [0007] This invention relates in general to corneal reconstruction and in particular to a method and means of regenerating a corneal lamella membrane in an effort to restore vision in patients suffering from failed Laser Corneal Ablation Procedure (LCAP) such as those described as LASIK or LASEK, radial keratomy, keratoconus, corneal abrasions, and trauma. Further, this invention holds promise as a method to devise a integral refractive correcting contact-like lens which can be ...

AI Technical Summary

Benefits of technology

The patent is about a method and means for regenerating a corneal lamella membrane to restore vision in patients who have failed Laser Corneal Ablation Procedure (LCAP) and are struggling with impaired vision. The invention is also about creating an integral refractive correcting contact-like lens that can be implanted on top of or into the corneal stroma. The technical effects of the invention include restoring vision in patients who have failed LCAP, providing a better understanding of the corneal damage caused by LCAP, and developing a method for regenerating corneal tissue using stem cells. The invention also addresses the problem of limited supplies of suitable donor tissue for corneal transplant. Previous attempts to correct the corneal structure have been hindered by the fact that only a fixed quantity of tissue is available for ablative modification. The invention aims to overcome these limitations and provide a more effective method for regenerating corneal tissue.

Problems solved by technology

Corneal damage is a leading cause of impaired vision and blindness.

Scarring due to chemical burns, missile damage, genetic disorders, radial keratomy, or failed LCAP are leading causes of corneal eye damage.

In particular, failed LCAP is the most common source of vision loss due to corneal damage.

Refractive complications can include too much or too little correction, or an imbalance in correction between the eyes.

In some cases, patients who experience improper LCAP may be left near or farsighted or with astigmatism, necessitating spectacles or contact lens wear, or in severe cases, may be faced with blindness.

Corneal inflammation is another side effect, which can cause a swelling known as diffuse interface keratitis, leading to corneal hazing, and ultimately, blurred vision.

However, all ophthalmologists readily admit, in their FDA-mandated informed consent that not everyone sees well enough after a LCAP procedure to truly eliminate their use of glasses and contact lenses.

In fact, studies have shown that over 2 percent of LCAP patients experience degradation in visual acuity that was uncorrectable through refractive means.

This is particularly troublesome since, unlike cataract surgery, which restores vision in defective eyes, LCAP is an elective process practiced on healthy eyes.

Further, intraoperative complications include decentered ablations and flap complications, such as a partial or lost flap.

Previous attempts to correct the corneal structure to alleviate the aforementioned conditions have been hampered by the fact that only a fixed quantity of tissue is available for ablative modification.

By its' very nature, laser ablation or LCAP removes healthy tissue, thus undermining the structural integrity of the cornea.

Replacement tissue is not available due to the fact that no other part of the body has the specialized collagen fibril structure inherent in the cornea.

However, problems of tissue rejection, of immunosuppressive medication, gross refractive errors, and limited supplies of suitable donor tissue hamper transplants.

While numerous experiments have been conducted in an effort to create laboratory-grown corneal tissue in vitro, the drawback of most of these methods is that they attempt to generate only one type of corneal cell structure, such as the epithelial or endothelial layers.

Stromal creation in the laboratory has in the past been met with limited success since no means have been found that successfully form the delicate collagen fibrils with micron sized diameters and fibril spacing necessary for corneal transparency and diffusive permeability.

Many prior art techniques rely on implanting a polymer of material (other than collagen or collagen that is devoid of fibrils), thus lacking in permeability as well as transparency inherent in native tissue.

This concept suffers from the fact that the lack of a controlled fibril diameter and fibril organizational structure significantly hinders the osmotic pumping of proteins and aqueous media through the fabricated collagen region.

As a result, transparency will be impaired.

Again, any means of producing a polymer implant which reduces the diffusion rate of oxygen, lipids, or aqueous media, reduces the effectiveness of the implant.

Subtle changes in the intraocular pumping mechanism can cause significant loss in visual acuity.

While providing improvements over simple collagen or other polymer implants, this suffers from the fact that the polymerized collagenous core does not contain fibrils at all as native tissue.

As such, the permeability of the implant is low, thus affecting corneal hydration and overall nutritional levels.

Further, since the collagen source employed can be derived from nonhuman sources, there is a susceptibility to immunologic effects.

While this coating does improve epithelial adhesion, the problems of lack of diffusibility, optical clarity, and foreign body rejection are still present.

This procedure suffers from the fact that any gel lacks inherent structural integrity and thus can only augment existing tissue through limited hydrodynamic forces.

This product suffers from the fact that as essentially a simple buffered isotonic saline solution, it is incapable of rendering any of the structural changes in the cornea required to correct high astigmatism, keratoconus, ectasia, burns, or corneal thinning.

Further, the solution of Ohuchi and Kato is capable only of yielding temporary corneal surface relief due to minor, transient optical modifications.

In reality, the electric charge that builds up on an electrospun fiber is significant, and results in whipping effect, which can vary fiber diameter and make precise deposition impossible as the fiber splays about the target.

This process repeats itself, leading an uncontrolled ability to deposit material at a precise target and pattern.

Further, the splaying about of the fibers results in tensile forces which varies the fiber diameter considerably.

However, cell and vessel in growth are detrimental to a successful corneal collagen fibril structure and if allowed to transpire, would result in blindness.

And the lack of such exact fibril specification, uniform diameter, and matrix pattern would result in reduced optical transparency of the material and insufficient permeability for ocular use.

Images